↓ Skip to main content

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

Overview of attention for article published in Cancer Communications, June 2019
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#39 of 118)
  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
Published in
Cancer Communications, June 2019
DOI 10.1186/s40880-019-0383-7
Pubmed ID
Authors

Ming Zhou, Xiaoyuan Chen, Hong Zhang, Lin Xia, Xin Tong, Limin Zou, Ruimin Hao, Jianhong Pan, Xiao Zhao, Dongmei Chen, Yuanyuan Song, Yueli Qi, Ling Tang, Zhifang Liu, Rong Gao, Yuankai Shi, Zhimin Yang

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Other 5 13%
Student > Bachelor 5 13%
Student > Postgraduate 5 13%
Student > Master 4 10%
Student > Ph. D. Student 2 5%
Other 5 13%
Unknown 13 33%
Readers by discipline Count As %
Medicine and Dentistry 12 31%
Biochemistry, Genetics and Molecular Biology 3 8%
Unspecified 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Chemistry 2 5%
Other 2 5%
Unknown 16 41%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2019.
All research outputs
#10,405,168
of 16,297,720 outputs
Outputs from Cancer Communications
#39
of 118 outputs
Outputs of similar age
#157,763
of 266,475 outputs
Outputs of similar age from Cancer Communications
#1
of 1 outputs
Altmetric has tracked 16,297,720 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 118 research outputs from this source. They receive a mean Attention Score of 3.9. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,475 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them